This page shows the latest vedolizumab news and features for those working in and with pharma, biotech and healthcare.
vedolizumab. Entyvio. Takeda. Ulcerative Colitis and Crohn's Disease. sacubitril/ valsartan. Entresto.
Takeda has high hopes for ixazomib, billing it as the company's second 'global launch' after ulcerative colitis therapy Entyvio (vedolizumab) - in other words a product that it will launch not
NICE has recommended Entyvio (vedolizumab) to treat moderate to severe ulcerative colitis in final draft guidance. ... Vedolizumab works in a different way to other treatment options [by] targeting the immune system in the gut rather than the whole body
Professor Carole Longson, director of NICE's health technology evaluation centre, said: “ Unfortunately the maker of vedolizumab did not give the committee enough information to show how well it worked when
These include the recently-approved Entyvio (vedolizumab) for Crohn's disease and ulcerative colitis, ixazomib (MLN9708) for multiple myeloma and alisertib (MLN8237) for peripheral T cell lymphoma.
However, the company's Entyvio (vedolizumab) has received approvals this year in both the EU and US for use in Crohn's disease and ulcerative colitis.
More from news
Approximately 8 fully matching, plus 9 partially matching documents found.
There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel (TAK-700),
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.